The clinical value of [18F]fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors

Endocrine-Related Cancer

Volumn 16, Issue 1, 2009, Pages 255-265

  Kauhanen, Saila ^a   Seppaänen, Marko ^a   Ovaska, Jari ^a   Minn, Heikki ^a   Bergman, Jörgen ^b   Korsoff, Pirkko ^c   Salmela, Pasi ^d   Saltevo, Juha ^e   Sane, Timo ^f   Välimäki, Matti ^f   Nuutila, Pirjo ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c SATAKUNTA CENTRAL HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e Central Hospital of Middle Finland   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; INSULIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TUMOR MARKER; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CUSHING DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; INSULINOMA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEUROENDOCRINE TUMOR; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREAS ISLET CELL HYPERPLASIA; PANCREAS SURGERY; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; UROGENITAL TRACT CANCER; WHOLE BODY PET; ADRENAL TUMOR; CLINICAL TRIAL; GASTROINTESTINAL TUMOR; LABORATORY DIAGNOSIS; MEDULLARY CARCINOMA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; STANDARD; THYROID TUMOR; VALIDATION STUDY;

ADRENAL GLAND NEOPLASMS; ADULT; CARCINOMA, MEDULLARY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 65549141729     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0229     Document Type: Article

References (38)

1. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH & Hor G 1998 Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. European Journal of Nuclear Medicine 25 79-83.
2. Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Langstrom B & Oberg K 1995 Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195 333-337.
3. Becherer A, Szabo M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R & Kletter K 2004 Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. Journal of Nuclear Medicine 45 1161-1167.
4. Bergman J, Haaparanta M, Lehikoinen P & Solin O 1994 Electrophilic synthesis of 6-18Ffuoro-L-dopa starting from aqueous-18Ffluoride. Journal of Labelled Compounds & Radiopharmaceuticals 35 476-477.
5. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K & Langstrom B 2000 Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Quarterly Journal of Nuclear Medicine 44 68-76.
6. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R & Virgolini IJ 2007 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Journal of Nuclear Medicine 48 508-518.
7. Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM & Park JG 1988 Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Research 48 4078-4082.
8. Gibril F & Jensen RT 2004 Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Digestive and Liver Disease 36 S106-S120.
9. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP et al. 2001 [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 685-693.
10. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E & Nitzsche E 2001 a 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. European Journal of Nuclear Medicine 28 64-71.
11. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E & Nitzsche E 2001b Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220 373-380.
12. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E & Neumann HP 2002 Pheochromocytomas: detection with 18F DOPA whole body PET - initial results. Radiology 222 507-512.
13. Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E & Neumann HP 2003 18F-DOPA positron emission tomography for the detection of glomus tumours. European Journal of Nuclear Medicine and Molecular Imaging 30 689-694.
14. Jadvar H & Segall GM 1997 False-negative fluorine-18-FDG PET in metastatic carcinoid. Journal of Nuclear Medicine 38 1382-1383.
15. Kauhanen S, Seppanen M, Minn H, Gullichsen R, Salonen A, Alanen K, Parkkola R, Solin O, Bergman J, Sane T et al. 2007 Fluorine-18-L-dihydroxyphenylalanine (18FDOPA) positron emission tomography as a tool to localize an insulinoma or β-cell hyperplasia in adult patients. Journal of Clinical Endocrinology and Metabolism 92 1237-1244.
16. Kauhanen S, Seppanen M & Nuutila P 2008 Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. Journal of Clinical Oncology 26 5307-5308.
17. Kloppel G, Rindi G, Anlauf M, Perren A & Komminoth P 2007 Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Archiv 451 S9-S27.
18. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN & Jager PL 2006 Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncology 7 728-734.
19. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL & de Vries EG 2008 Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. Journal of Clinical Oncology 26 1489-1495.
20. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M & Reubi JC 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123ITyr3]-octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 20 716-731.
21. Kumar J, Spring M, Carroll PV, Barrington SF & Powrie JK 2006 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clinical Endocrinology 64 371-374.
22. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, Norton JA, Walther MM, Keiser HR & Neumann RD 1993 Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. Journal of Nuclear Medicine 34 173-179.
23. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle FG, Kaltsas GA, Krenning EP et al. 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72.
24. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de B V, Aide N, Gutman F, Grange JD, Lotz JP & Talbot JN 2006 Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? Journal of Nuclear Medicine 47 1455-1462.
25. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, BergstromM& Eriksson B 2005 Wholebody (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. Journal of Clinical Endocrinology and Metabolism 90 3392-3400.
26. Orlefors H, Sundin A, Lu L, Oberg K, Langstrom B, Eriksson B & Bergstrom M 2006 Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 33 60-65.
27. Otonkoski T, Nanto-Salonen K, Seppanen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekstrom K et al. 2006 Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes 55 13-18.
28. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST & Goldstein DS 2001 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38 6-8.
29. Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M & Nieman LK 2004 The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylene- triaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 89 2214-2221.
30. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G & Pedrazzoli S 1998 Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World Journal of Surgery 22 588-592.
31. Pearse AG 1969 The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. Journal of Histochemistry and Cytochemistry 17 303-313.
32. Reubi JC, Schaer JC, Waser B & Mengod G 1994 Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Research 54 3455-3459.
33. Rufini V, Calcagni ML & Baum RP 2006 Imaging of neuroendocrine tumors. Seminars in Nuclear Medicine 36 228-247.
34. Shulkin BL, Thompson NW, Shapiro B, Francis IR & Sisson JC 1999 Pheochromocytomas: imaging with 2-[fluorine- 18]fluoro-2-deoxy-D-glucose PET. Radiology 212 35-41.
35. Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, Ling A, Eisenhofer G, Adams KT & Pacak K 2007a The effects of carbidopa on uptake of 6-18FFluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. Journal of Nuclear Medicine 48 1599-1606.
36. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW & Pacak K 2007b Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. Journal of Clinical Oncology 25 2262-2269.
37. Trampal C, Engler H, Juhlin C, Bergstrom M & Langstrom B 2004 Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology 230 423-428.
38. Wright BE, Lee CC & Bilchik AJ 2007 Hepatic cytoreductive surgery for neuroendocrine cancer. Surgical Oncology Clinics of North America 16 627-637.